Rapid Communication
Copyright ©2007 Baishideng Publishing Group Inc.
World J Gastroenterol. Dec 14, 2007; 13(46): 6191-6196
Published online Dec 14, 2007. doi: 10.3748/wjg.v13.i46.6191
Table 1 Sequence primers used for detection of NOD2 mutations
PrimersSequence
Arg702W (forward)5’-GGCGCCCCTGGAATTC-3’
Arg702W (reverse)5’-CCTCACCCGGTGCAGC-3’
Gly908Arg (forward)5’-CCCAGCTCCTCCCTCTTTC-3’
Gly908Arg (reverse)5’-AAGTCTGTAATGTAAACGCCAC-3’
Leu1007fsinsC (forward)5’-GAATGTCAGAATCAGAAGGG-3’
Leu1007fsinsC (reverse)5’-GTCTCACCATTGTATCTTCTTTTC-3’
Table 2 Genotype and allelic frequencies for NOD2 variants in CD patients and controls
CD (n = 47)Healthy controls (n = 69)
Genotype
Hz17/47 (36.1%)4/69 (5.8%)
Double Hz3/47 (6.4%)0
mtNOD220/474/69
wtNOD227/470/69
Allelic frequencies
R702W5.30%1.45%
G908R7.45%0.75%
1007fs8.50%0.75%
Table 3 CDAI and drug therapy in mtNOD2 and wtNOD2 patients
mtNOD2 (n = 20)wtNOD2 (n = 27)
CDAI24.525.2
Active disease1416
Steroids79
Methotrexate11
Azathioprine45
Aminosalicylic acid68
Salazopyrine44
Infliximab11
Thalidomide45